On February 27, 2026, HHS Secretary RFK Jr. announced 14 peptides will move from FDA Category 2 back to Category 1. Complete guide to which compounds are affected, what changes, and what stays the same.
The Announcement That Changed Everything On February 27, 2026, while appearing on Episode 2461 of the Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides placed on the FDA Category 2 restricted list in 2023 will be moved back to Category 1 -- restoring eligibility for legal compounding by licensed pharmacies under physician prescription. This is the most significant regulatory shift in US peptide therapy access in the past decade.
In late 2023, the FDA moved 19 widely used peptides to its Category 2 bulk drug substances list -- a designation indicating the agency believed these compounds presented significant safety risks that precluded their use in compounding.
The practical effect: licensed 503A and 503B compounding pharmacies could no longer legally prepare these peptides for patients. Physicians who had been prescribing compounds like BPC-157, TB-500, and Thymosin Alpha-1 through legitimate pharmaceutical channels lost access virtually overnight.
Kennedy's announcement contained two key claims. First, that approximately 14 of the 19 restricted peptides would be moved back to Category 1. Second, that the original restrictions had been applied without the specific safety signal required by law -- they were based on lack of efficacy data, not evidence of actual harm. "We created the gray market," Kennedy acknowledged, noting that the ban had driven patients toward unregulated online vendors.
Healing and Recovery: BPC-157 (Body Protection Compound-157), TB-500 (Thymosin Beta-4), KPV (tripeptide anti-inflammatory)
Growth Hormone Axis: CJC-1295 (GHRH analog), Ipamorelin (selective GHRP), GHRP-2, GHRP-6, Sermorelin
Immune Support: Thymosin Alpha-1
Longevity and Anti-Aging: Epithalon, GHK-Cu (copper peptide), MOTS-c, Selank, AOD-9604
Note: The FDA has not published a formal updated list as of this writing. The above represents expert prediction based on the announcement, not official confirmation.
Category 1 status means a compound is eligible for use by licensed 503A compounding pharmacies (individual prescriptions) while under FDA evaluation. It does NOT mean FDA approval.
Critical distinctions:
If you have been accessing peptides through gray-market research chemical vendors, the reclassification creates a path to pharmaceutical-grade product through a physician. Pharmaceutical-grade compounded peptides offer independent third-party purity testing and accurate concentration -- independent testing of research chemicals consistently shows plus or minus 40-300% concentration variance vs plus or minus 10% for pharmacy-grade product.
Whether you are currently running peptides through existing channels or planning to start once pharmacy access normalizes, tracking your biomarkers is the most important thing you can do to know whether your protocol is working.
MyProtocolStack tracks 40 or more biomarkers with optimal ranges, integrates StackAI blood work analysis, and logs your dose history alongside your lab draws.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →